D
Dariusz M. Kowalski
Researcher at Curie Institute
Publications - 161
Citations - 12935
Dariusz M. Kowalski is an academic researcher from Curie Institute. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 25, co-authored 129 publications receiving 7930 citations.
Papers
More filters
Journal ArticleDOI
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.
Paweł Krawczyk,Dariusz M. Kowalski,Rodryg Ramlau,Ewa Kalinka‑Warzocha,Kinga Winiarczyk,Katarzyna Stencel,Tomasz Powrózek,Katarzyna Reszka,Kamila Wojas Krawczyk,Maciej Bryl,Magdalena Wójcik‑Superczyńska,Maciej Głogowski,Aleksander Barinow Wojewódzki,Janusz Milanowski,Maciej Krzakowski +14 more
TL;DR: A retrospective analysis of 180 NSCLC patients with common and rare EGFR mutations treated with erlotinib, gefit inib, and afatinib showed similar efficacies based on treatment response, median PFS, and OS, suggesting that when undergoing EGFR-TKI treatment, patients with rare EG FR mutations showed similar OS but poorer PFS.
Journal ArticleDOI
ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,N. Fujimoto,Solange Peters,Anne Tsao,Aaron S. Mansfield,Sanjay Popat,T. Jahan,S.J. Antonia,Youssef Oulkhouir,Y. Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz M. Kowalski,Jerónimo Rodríguez-Cid,Praveen Aanur,Christine Baudelet,Gérard Zalcman +19 more
Journal ArticleDOI
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Julien Mazieres,Dariusz M. Kowalski,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Konstantin Laktionov,Barbara Hermes,Irfan Cicin,Jerónimo Rodríguez-Cid,Jonathan Wilson,Terufumi Kato,Rodryg Ramlau,Silvia Novello,Sreekanth Reddy,Hans-Georg Kopp,Bilal Piperdi,Xiaodong Li,Thomas Burke,Luis Paz-Ares +19 more
TL;DR: The results support use of pembrolizumab plus chemotherapy as first-line therapy for metastatic squamous NSCLC and maintained or improved HRQoL measurements relative to baseline and improved HRZoL versus chemotherapy alone at weeks 9 and 18.
Journal ArticleDOI
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.
Hedy L. Kindler,Arnaud Scherpereel,Luana Calabrò,Joachim G.J.V. Aerts,Susana Cedres Perez,Alessandra Bearz,Kristiaan Nackaerts,Dean A. Fennell,Dariusz M. Kowalski,Anne S. Tsao,Paul D. Taylor,Federica Grosso,Scott J. Antonia,Anna K. Nowak,Ramy Ibrahim,Maria Taboada,Martina Puglisi,Paul K. Stockman,Michele Maio +18 more
TL;DR: Single-arm Phase 2 trials of T using 2 different doses and schedules achieved responses and durable disease control in MM pts with unresectable pleural or peritoneal MM.
Proceedings ArticleDOI
Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
Byoung Chul Cho,Gilberto Lopes,Dariusz M. Kowalski,Kazuo Kasahara,Yi-Long Wu,Gilberto de Castro,Hande Turna,Razvan Cristescu,Deepti Aurora-Garg,Andrey Loboda,Jared Lunceford,J. Kobie,Mark Ayers,M. Catherine Pietanza,Bilal Piperdi,Tony Mok +15 more
TL;DR: Pembrolizumab monotherapy should be considered a standard first-line treatment option for advanced PD-L1-positive NSCLC regardless of STK11 or KEAP1 status, according to the findings of this exploratory analysis of KEYNOTE-042.